A Study Evaluating the Effectiveness and Safety of Pulsed Field Ablation Using the FARAPULSE™ System for Electrical Isolation of Pulmonary Veins and Superior Vena Cava
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pulsed Field Ablation.
- Who it may be relevant to
- Registry conditions: Atrial Fibrillation (Paroxysmal). Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a prospective, single-center, single-arm clinical trial planning to screen and enroll 200 subjects. It aims to evaluate the efficacy and safety of pulsed field ablation (PFA) using the FARAPULSE™ system for pulmonary vein isolation (PVI) and superior vena cava isolation (SVCI) in Chinese patients with paroxysmal atrial fibrillation (PAF). Baseline preoperative data, along with intraoperative and postoperative follow-up information, will be collected. The primary endpoint is the proportion of subjects achieving successful PVI and SVCI using solely the FARAPULSE™ PFA system. Secondary endpoints include long-term procedural success rates and various procedural parameters. Additionally, the incidence of adverse events will be recorded as safety endpoints. The study adopts a single-arm target value design hypothesis, and research data will also be compared with historical data from patients treated with radiofrequency ablation for PVI and SVCI to further evaluate the efficacy of PFA. Subgroup analysis will be conducted in patients with heart failure to assess the efficacy and safety of PFA in this population.
Interventions
- Device Pulsed Field Ablation
Pulsed Field Ablation
Primary outcome measures
- PVI and SVCI [Time frame: Periprocedural]
Secondary outcome measures (2)
- Long-term procedural success rates [Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up]
- Perioperative complications [Time frame: From the end of the ablation to the 12-month follow-up]
Eligibility criteria
Inclusion criteria
- Age between 18 and 75 years.
- Documented diagnosis of paroxysmal atrial fibrillation (PAF), defined as typical AF electrographic characteristics (absence of P waves with irregular fibrillatory waves) recorded on 12-lead ECG or symptomatic Holter monitoring, with each episode lasting less than 7 days.
- Symptomatic despite attempted antiarrhythmic drug therapy.
- Scheduled to undergo initial catheter ablation procedure.
- Voluntarily provided written informed consent.
Exclusion criteria
- AF secondary to electrolyte imbalance, thyroid disorders, or other reversible/non-cardiac causes.
- Persistent atrial fibrillation.
- Presence of persistent left superior vena cava.
- Contraindications to pulsed field ablation (e.g., left atrial appendage thrombus, post-atrial septal defect device closure, permanent metallic implants in the left atrium) or contraindications to anticoagulant therapy.
- Unsuitable for deep sedation/anesthesia per operator assessment.
- Life expectancy less than 1 year.
- Other conditions deemed inappropriate for inclusion by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07162597 · B2025-426R